Key result
Ticagrelor significantly reduced the risk of vascular death, MI, or stroke compared with clopidogrel in patients with acute coronary syndromes (9.8% vs 11.7%; HR 0.84; 95% CI 0.77-0.92; P<0.001).
Why the study?
Does ticagrelor reduce the risk of death from vascular causes, MI, or stroke compared to clopidogrel in patients with acute coronary syndromes?
Population
18,624 patients with acute coronary syndromes (ACS)
Comparison
Ticagrelor vs Clopidogrel
Design
Review
Follow-up
12 months
Authors
Loading...
May support ticagrelor preference in ACS; leaves open questions on bleeding and long-term outcomes in contemporary cohorts.
Does ticagrelor reduce the risk of death from vascular causes, MI, or stroke compared to clopidogrel in patients with acute coronary syndromes?
Hazard Ratio: 0.84 (95% CI 0.77–0.92)
Absolute Event Rate: 9.8% vs 11.7%
p-value: p=< 0.001
In patients with acute coronary syndromes, ticagrelor reduces the composite of vascular death, MI, or stroke compared to clopidogrel without significantly increasing major bleeding.
Steen Husted (2011) conducted a review in Acute coronary syndromes (ACS) (n=18,624). Ticagrelor vs. Clopidogrel was evaluated on death from vascular causes/myocardial infarction (MI)/stroke (HR 0.84, 95% CI 0.77-0.92, p=< 0.001). Ticagrelor significantly reduced the risk of vascular death, MI, or stroke compared with clopidogrel in patients with acute coronary syndromes (9.8% vs 11.7%; HR 0.84; 95% CI 0.77-0.92; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: